Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Subasumstat - Takeda Oncology

Next Previous
X
Search
Drug Profile

Subasumstat - Takeda Oncology

Alternative Names: TAK-981

Latest Information Update: 12 Aug 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Takeda Oncology
  • Developer Presage Biosciences; Takeda Oncology
  • Class Amines; Antineoplastics; Chlorinated hydrocarbons; Cyclopentanes; Isoquinolines; Pyrimidines; Small molecules; Sulfonamides; Thiophenes
  • Mechanism of Action Small ubiquitin-related modifier protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Lymphoma; Multiple myeloma; Non-Hodgkin's lymphoma; Solid tumours
  • No development reported B-cell lymphoma; Chronic lymphocytic leukaemia; Head and neck cancer

Most Recent Events

  • 16 Jul 2024 Takeda terminates a phase I trial in Solid tumours (Late-stage disease, Metastatic Disease, Second-line therapy or greater) in Hungary due to business reasons (IV, Infusion) (NCT05976334)
  • 07 Apr 2024 Pharmacodynamics data from a preclinical study in Synovial sarcoma presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 21 Mar 2024 Phase-I/II clinical trials in Solid tumours (Combination therapy, Second-line therapy or greater, Late-stage disease, Metastatic disease) in Brazil, China, Croatia, Japan, Latvia, Lithuania, Poland, Switzerland (IV) (NCT04381650)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top